Left ventricular wall stress-mass-heart rate product and cardiovascular events in treated hypertensive patients: Life study

Hypertension

Volumn 66, Issue 5, 2015, Pages 945-953

  Devereux, Richard B ^a   Bang, Casper N ^a   Roman, Mary J ^a   Palmieri, Vittorio ^a   Boman, Kurt ^b   Gerdts, Eva ^c   Nieminen, Markku S ^d   Papademetriou, Vasilios ^e   Wachtell, Kristian ^f   Hille, Darcy A ^g   Dahlöf, Björn ^h  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UMEÅ UNIVERSITY   (Sweden)

^c UNIVERSITY OF BERGEN   (Norway)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e S G MOSCATI HOSPITAL   (Italy)

^f GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^g MERCK RESEARCH LABORATORIES   (United States)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

hypertension; hypertrophy; myocardial infarction; oxygen; prognosis

Indexed keywords

ATENOLOL; LOSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; OXYGEN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; WALL STRESS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMPLICATION; DRUG EFFECTS; HEART VENTRICLE; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; MIDDLE AGED; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; FEMALE; HEART RATE; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OXYGEN; PREVALENCE; STROKE; TREATMENT OUTCOME;

EID: 84943403787     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.05582     Document Type: Article

References (35)

1. Devereux RB, Alderman MH., Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 1993 88 4 pt 1 1444 1455
2. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH., Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991 114 345 352
3. Mensah GA, Pappas TW, Koren MJ, Ulin RJ, Laragh JH, Devereux RB., Comparison of classification of the severity of hypertension by blood pressure level and by World Health Organization criteria in the prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension. J Hypertens 1993 11 1429 1440
4. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP., Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990 322 1561 1566. doi: 10.1056/NEJM199005313222203
5. Bikkina M, Levy D, Evans JC, Larson MG, Benjamin EJ, Wolf PA, Castelli WP., Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA 1994 272 33 36
6. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK., The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995 273 1592 1597
7. Liao Y, Cooper RS, Durazo-Arvizu R, Mensah GA, Ghali JK., Prediction of mortality risk by different methods of indexation for left ventricular mass. J Am Coll Cardiol 1997 29 641 647
8. Bolognese L, Dellavesa P, Rossi L, Sarasso G, Bongo AS, Scianaro MC., Prognostic value of left ventricular mass in uncomplicated acute myocardial infarction and one-vessel coronary artery disease. Am J Cardiol 1994 73 1 5
9. Dahlöf B, Devereux R, De Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H., The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997 10 7 pt 1 705 713
10. Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, De Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristiansson K, Lederballe-Pedersen, Lindholm LH, Nieminen M, Omvik P, Oparil S, Wedel H, for the LIFE Study Group Characteristics of 9,194 patients with left ventricular hypertrophy: The Losartan Intervention for Endpoint (LIFE) Reduction in Hypertension Study. Hypertension 1998 32 989 997. doi: 10.1161/01.HYP.32.6.989
11. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002 359 995 1003. doi: 10.1016/S0140-6736(02)08089-3
12. Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K., Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004 110 1456 1462. doi: 10.1161/01.CIR.0000141573.44737.5A.
13. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B, Losartan Intervention for Endpoint reduction in hypertension Study Investigations Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003 108 684 690. doi: 10.1161/01.CIR.0000083724.28630.C3
14. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B., Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004 292 2350 2356. doi: 10.1001/jama.292.19.2350
15. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B, LIFE Study Investigators Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004 292 2343 2349. doi: 10.1001/jama.292.19.2343
16. Koyanagi S, Eastham CL, Harrison DG, Marcus ML., Increased size of myocardial infarction in dogs with chronic hypertension and left ventricular hypertrophy. Circ Res 1982 50 55 62
17. Dellsperger KC, Clothier JL, Hartnett JA, Haun LM, Marcus ML., Acceleration of the wavefront of myocardial necrosis by chronic hypertension and left ventricular hypertrophy in dogs. Circ Res 1988 63 87 96
18. Koyanagi S, Eastham C, Marcus ML., Effects of chronic hypertension and left ventricular hypertrophy on the incidence of sudden cardiac death after coronary artery occlusion in conscious dogs. Circulation 1982 65 1192 1197
19. Sarnoff SJ, Braunwald E, Welch GH Jr, Case RB, Stainsby WN, Macruz R., Hemodynamic determinants of oxygen consumption of the heart with special reference to the tension-time index. Am J Physiol 1958 192 148 156
20. Inou T, Lamberth WC Jr, Koyanagi S, Harrison DG, Eastham CL, Marcus ML., Relative importance of hypertension after coronary occlusion in chronic hypertensive dogs with LVH. Am J Physiol 1987 253 5 Pt 2 H1148 H1158
21. Devereux RB, Roman MJ, Palmieri V, Okin PM, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Wachtell K, Dahlöf B., Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. Losartan Intervention For Endpoint reduction in hypertension. J Hypertens 2000 18 1129 1138
22. Devereux RB, Bella J, Boman K, Gerdts E, Nieminen MS, Rokkedal J, Papademetriou V, Wachtell K, Wright J, Paranicas M, Okin PM, Roman MJ, Smith G, Dahlöf B., Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press 2001 10 74 82
23. Molloy TJ, Okin PM, Devereux RB, Kligfield P., Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol 1992 20 1180 1186
24. Okin PM, Roman MJ, Devereux RB, Kligfield P., Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995 25 417 423
25. Sahn DJ, DeMaria A, Kisslo J, Weyman A., Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978 58 1072 1083
26. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I., Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989 2 358 367
27. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N., Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986 57 450 458
28. Gaasch WH, Zile MR, Hoshino PK, Apstein CS, Blaustein AS., Stress-shortening relations and myocardial blood flow in compensated and failing canine hearts with pressure-overload hypertrophy. Circulation 1989 79 872 883
29. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB., Association of carotid atherosclerosis and left ventricular hypertrophy. J Am Coll Cardiol 1995 25 83 90
30. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB., Relation of arterial structure and function to left ventricular geometric patterns in hypertensive adults. J Am Coll Cardiol 1996 28 751 756
31. Scheike TH., Analyzing competing risk data using R timesreg package. J Statistical Software 2011 38 1 15
32. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. [No authors listed]. N Eng J Med 1981 304 801 807
33. Okin PM, Hille DA, Kjeldsen SE, Dahlöf B, Devereux RB., Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive treatment. Blood Press 2014 23 71 80. doi: 10.3109/08037051.2013.791414
34. Dahlöf B, Burke TA, Krobot K, Carides GW, Edelman JM, Devereux RB, Diener HC., Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Hum Hypertens 2004 18 367 373. doi: 10.1038/sj.jhh.1001710
35. Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction Universal definition of myocardial infarction. Circulation 2007 116 2634 2653. doi: 10.1161/CIRCULATIONAHA.107.187397